Similar results were obtained by Briere et al., demonstrating that mocetinostat, a class I/IV HDAC inhibitor, upregulated antigen presentation genes (HLA) and PD-L1 expression in many NSCLC cell lines in vitro. Here, HDAC9 is linked to non-small cell lung carcinoma.